Press - MariMed

MariMed Reports Record Fourth Quarter and Full Year 2020 Financial Results and Provides Full Year 2021 Guidance

Achieves Record Results Driven by Continued Consolidation of Cannabis Operations Core Cannabis Revenue Increased 292% in Q4 2020 ($20.4m) and 207% in FY 2020 ($50.9 m) Reports Q4 2020 EBITDA of $7.7 Million and $16.3 Million for FY 2020 Secures Long Term Capital Partner – Company Generating Positive Operating Cash Flow Provides Full Year 2021 Revenue Guidance of $100 million and EBITDA of $30...

MariMed Secures New Funding from Long-Term Capital Partner

Capital Infusion to Strengthen Balance Sheet and Provide Funding for Strategic Acquisitions $46 Million Dollar Financing Facility to Accelerate Company Growth Strategy NORWOOD, Mass., March 2, 2021 /CNW/ - MariMed, Inc. (OTCQX: MRMD) (the "Company" or "MariMed"), a leading multi-state cannabis operator focused on health and wellness, today announced the closing of a $46 million financing facility...

Chews Love: MariMed Launches Cannabis-Infused Betty’s Eddies™ “Smashin’ Passion” Aphrodisiac Chews

New passionfruit-flavored cannabis edibles made with four all-natural aphrodisiac ingredients Available for Valentine’s Day in MA, NV, and RI; widely available in other markets by March 2021 Marks 10th flavor and formulation for award-winning Betty’s Eddies brand NORWOOD, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Move over, flowers and chocolate. Leading multi-state cannabis operator MariMed Inc....

MariMed: The Hottest Selling Edibles And Why You Should Own This Stock

Originally Appeared in Seeking Alpha. Summary MariMed prints positive net earnings and is set to continue this trend; With #1 selling edibles products, MariMed could grow revenues beyond projections as more dispensaries take on new products; Future earnings projections could push stock price upwards some 400%. "Many of the cannabis companies I follow are either just on the brink of finally...